TABLE 3

FIC testing of PT plus rifampin against clinical isolates

StrainMIC (µg · ml−1)FIC indexa
AloneCombination
PTbRifampinPTRifampin
P. aeruginosa
    PAO10.4115.60.211.90.634
    RW010.4115.60.131.90.439
    RW020.4115.60.161.90.512
    RW030.5115.60.163.90.564
    RW040.3215.60.131.90.528
    RW050.3231.250.131.90.467
    RW060.3215.60.131.90.528
    RW070.3215.60.131.90.528
S. aureus
    UAMS-12.10.010.670.00150.469
    11109361.60.050.670.00350.489
    11110632.10.10.670.00760.395
    10717881.60.010.670.00150.569
    1103430c2.10.010.670.00150.469
    1094094c2.10.010.670.00150.469
    1094140c2.10.010.670.00150.469
    10941472.10.010.670.00150.469
    10941662.10.010.670.00150.469
    10941782.10.10.670.00760.395
    1144105c1.60.050.670.00350.489
    10976122.10.050.670.00350.389
    10976302.10.010.670.00150.469
    1122181c2.10.010.670.00150.469
    1122187c2.10.050.670.00350.389
    1122190c1.60.050.670.00350.489
    1122197c2.10.010.670.00150.469
    1132822c2.10.010.670.00150.469
    1101442c1.60.050.670.00350.489
    1142776c2.10.010.670.00150.469
    1125120c2.10.050.670.00760.471
    Vig R0.650.030.310.00780.75
  • a FIC, fractional inhibitory concentration.

  • b PT, polymyxin B-trimethoprim.

  • c Methicillin-resistant Staphylococcus aureus (MRSA).